Background: Beta-lactam antibiotic allergy labels are highly prevalent but rarely indicate an allergic intolerance. These patient-reported allergies lead to broad-spectrum antibiotic use, conferred resistance, increased expense, and adverse effects.
Objective: To implement and assess the impact of a history-based clinical guideline that directs antibiotic management and beta-lactam allergy relabeling for patients reporting beta-lactam allergies.
Methods: Patients with beta-lactam allergy labels were identified by our trained multidisciplinary team in diverse clinical settings. This quality improvement project was conducted to evaluate the safety and impact of the guideline on antibiotic use by comparing prescribing practices before and after guideline implementation.
Results: A total of 79 patients with beta-lactam allergies were identified (penicillins-90%, cephalosporins-10%). After guideline implementation, outcomes of allergy relabeling included the following: (1) complete removal, indicating an unlikely true allergy (27%); (2) updated to detail successfully tolerated beta-lactam courses (48%); or (3) no change made to current label (25%). Beta-lactam antibiotic courses before and after guideline implementation compared with total antibiotic courses: allergy removed (44% vs 70%; P < .001), allergy updated (32% vs 68%; P < .001), and no change (27% vs 41%; P = .08). Compared with before guideline implementation, beta-lactam antibiotics were 3 times more likely to be prescribed after allergy assessment (odds ratio, 3.22; 95% confidence interval, 2.4-4.3; P < .05).
Conclusion: The implementation of the beta-lactam allergy clinical guideline resulted in most patients' allergy labels being removed or advantageously updated. These allergy label changes correlated with a substantial increase in the percentage of beta-lactam antibiotics prescribed. After guideline implementation, beta-lactam antibiotics had a 3-fold increased odds of being prescribed independent of allergy label outcome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.anai.2021.12.004 | DOI Listing |
Front Allergy
December 2024
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, United States.
Appl Biosaf
December 2024
Royal Society of Biology, London, United Kingdom.
Introduction: Cephalosporins can trigger hypersensitivity reactions in certain individuals. Consequently, strict regulations restrict the production of non-beta-lactam substances during or after cephalosporin manufacturing. Dry chlorine dioxide gas (dClO), together with ultra-performance liquid chromatography Mass spectrometry/mass spectrometry (UPLC-MS/MS) detection methods, has emerged as a promising method for decontaminating cephalosporin compounds.
View Article and Find Full Text PDFAm J Health Syst Pharm
December 2024
Tufts Medical Center, Boston, MA, USA.
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFCureus
November 2024
Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, ESP.
This case report describes a 40-year-old male patient who developed symmetrical drug-related intertriginous and flexural exanthema after taking amoxicillin. Initial allergy testing showed negative intradermal tests, but subsequent drug provocation tests with amoxicillin and penicillin were positive, indicating cross-reactivity between these β-lactam antibiotics. Notably, following the final provocation test, the intradermal test with penicillin turned positive, demonstrating a flare-up phenomenon.
View Article and Find Full Text PDFAnaesth Crit Care Pain Med
December 2024
University Paris Cité, Paris, France; Anaesthesiology and Critical Care Medicine Department, DMU PARABOL, Bichat Hospital, AP-HP, Paris, France; Antibody in Therapy and Pathology, Pasteur Institute, UMR 1222 INSERM, Paris, France. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!